ArticleCancers2026

Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial.

Erel Joffe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.